Bird Flu Fears Stoke the Race for an mRNA Flu Vaccine

Concern over potential human-to-human transmission of bird flu has risen after six Missouri healthcare workers developed mild respiratory symptoms following contact with a patient infected with H5N1. The CDC reports only the original patient has tested positive for the virus. Scientists are ramping up efforts to develop mRNA vaccines against H5N1, with researchers at the University of Pennsylvania and major pharmaceutical companies like Moderna, Pfizer, and GSK leading the charge. While mRNA technology offers rapid vaccine production, clinical trials have shown mixed results, particularly against influenza B strains. Wired adds: Traditionally, flu vaccines contain inactivated viruses that are grown in hens' eggs. This works reasonably well, but it takes a long time to make such jabs, which means health authorities have to publish their predictions about which strains of flu will be circulating during the upcoming winter well in advance. If you could manufacture vaccines more quickly, you could make more accurate predictions nearer to flu season.

Not only that, researchers hope that a single mRNA shot could one day target 20 or more strains of flu at once, relieving the need for some of this guesswork. Scher's colleagues are working on such a 'universal' flu vaccine. With clinical trials ongoing, it's still early days. Sheena Cruickshank, an immunologist at the University of Manchester, has watched reports about emerging mRNA flu jabs with interest but says that questions remain. 'We don't yet know how long-lasting the immunity they produce is,' she says. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, concurs, though he notes that all flu jabs, regardless of how they are made, have a waning immunity problem -- your protection could decline by around 10 percent every month following injection.

Read more of this story at Slashdot.